Acute Effect of Caffeine-Based Multi-Ingredient Supplement on Reactive Agility and Jump Height in Recreational Handball Players.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

This study aimed to examine the acute effect of MS on the reactive agility and jump performance in recreational handball male players.

Why It Was Studied

A randomized, double-blind, crossover study involved twenty-four male handball players (body mass 74.6 ± 8.8 kg; body height 179 ± 7 cm; age 23.8 ± 1.4 years).

Participants were tested under three conditions: placebo, caffeine + guarana (CAF + GUA), or MS ingestion 45 min before exercise tests.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

In the crossover set-up each of the participants took both Copper (Supplement) and the comparison in turn, acting as their own control.

What Was Measured

Participants were tested under three conditions: placebo, caffeine + guarana (CAF + GUA), or MS ingestion 45 min before exercise tests.

Participants performed a reactive agility test (Y-shaped test) and countermovement jump (CMJ).

The subject headings attached to it are Athletic Performance, Body Height, Caffeine and Exercise Test.

The authors tagged it with the keywords agility test, countermovement jump and multi-ingredient supplement.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The publication is from 2022 (Nutrients), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.